08/03/22 8:00 AMNYSE : RFL clinical triallow floatCornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract CancerCornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the successful completion of a Phase 1b clinical trial of CPI-613 ®RHEA-AIvery positive
07/06/22 8:00 AMNYSE : RFL managementlow floatCornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the appointment of Jason Locasale, Ph.D., as a member of the Company’sRHEA-AIvery positive
06/27/22 8:00 AMNYSE : RFL conferencesclinical triallow floatCornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that data on its lead compound CPI-613 ® (devimistat) in combinationRHEA-AIneutral
06/16/22 2:14 PMNYSE : RFL low floatCornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATECornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data supporting CPI-613 ® (devimistat)RHEA-AIneutral
06/16/22 8:00 AMNYSE : RFL low floatCornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data supporting CPI-613 ® (devimistat)RHEA-AIneutral
06/14/22 4:01 PMNYSE : RFL earningslow floatRafael Holdings Reports Third Quarter Fiscal 2022 Financial ResultsRafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today reported its financial results for the three and nine months ended April 30, 2022. The Company is focused on accelerating theRHEA-AIneutral
06/01/22 8:00 AMNYSE : RFL conferenceslow floatCornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingCornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that the Company and its partners will present three abstracts at theRHEA-AIneutral
05/24/22 11:04 AMNYSE : RFL low floatEuropean Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract CancerCornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that the European Medicines Agency (EMA) has granted orphan drugRHEA-AIvery positive
05/19/22 9:00 AMNYSE : RFL low floatRafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the development of rare cancerRHEA-AIvery positive
03/17/22 4:01 PMNYSE : RFL earningslow floatRafael Holdings Reports Second Quarter Fiscal 2022 Financial ResultsRafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today reported its financial results for the three and six months ended January 31, 2022. The end of our second fiscal quarter marks aRHEA-AIneutral